Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma

Lignende værker

• Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma
  af: Fowler, Nathan H., et al.
  Udgivet: (2015)
• Safety, activity, and immune effects of lenalidomide and rituximab in untreated indolent lymphoma
  af: Fowler, Nathan H, et al.
  Udgivet: (2014)
• Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma
  af: Strati, Paolo, et al.
  Udgivet: (2021)
• AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma
  af: Leonard, John P., et al.
  Udgivet: (2019)
• Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis
  af: Zhang, Peng‐Fei, et al.
  Udgivet: (2020)